NCT06031480 - Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Anlotinib and TQB2450

"Anlotinib: 10mg PO, QD, D1-14, Q3W; TQB2450: 1200 mg, IV, D1, Q3W.~Anlotinib and TQB2450 will be administered until the disease progression, intolerable toxicity, death, withdrawal of consent."

Trial Locations (1)

200032

Zhongshan hospital, Shanghai